Clinical ribonucleotide reductase (RNR) inhibitors have reinvigorated enthusiasm for radiochemotherapy treatment of patients with regionally advanced stage cervical cancers. About two-thirds of patients outlive their cervical cancer (1), even though up to half of their tumors retain residual microscopic disease (2). The National Cancer Institute Cancer Therapy Evaluation Program conducted two prospective trials of triapine-cisplatin-radiation to improve upon this finding by precisely targeting cervical cancer's overactive RNR. Triapine's potent inactivation of RNR arrests cells at the G1/S cell cycle restriction checkpoint and enhances cisplatin-radiation cytotoxicity. In this article, we provide perspective on challenges encountered in and future potential of clinical development of a triapine-cisplatin-radiation combination for patients with regionally advanced cervical cancer. New trial results and review presented here suggest that a triapine-cisplatin-radiation combination may offer molecular cell cycle target control to maximize damage in cancers and to minimize injury to normal cells. A randomized trial now accrues patients with regionally advanced stage cervical cancer to evaluate triapine's contribution to clinical benefit after cisplatin-radiation (clinicaltrials.gov, NCT02466971).
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2018.
All research outputs
#17,292,294
of 25,382,440 outputs
Outputs from Frontiers in oncology
#8,031
of 22,428 outputs
Outputs of similar age
#220,759
of 341,525 outputs
Outputs of similar age from Frontiers in oncology
#86
of 153 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,428 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,525 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 153 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
